Intersect ENT (Intersect ENT) EPS (Basic) : $-5.04 (TTM As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT EPS (Basic)?

Intersect ENT's basic earnings per share (Basic EPS) for the three months ended in Mar. 2022 was $-0.85. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.04.

Intersect ENT's EPS (Diluted) for the three months ended in Mar. 2022 was $-0.85. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.04.

Intersect ENT's EPS without NRI for the three months ended in Mar. 2022 was $-0.85. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was -5.04.

During the past 3 years, the average EPS without NRI Growth Rate was -84.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -45.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Intersect ENT's highest 3-Year average EPS without NRI Growth Rate was 60.40% per year. The lowest was -84.80% per year. And the median was 8.70% per year.

Intersect ENT EPS (Basic) Historical Data

The historical data trend for Intersect ENT's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT EPS (Basic) Chart

Intersect ENT Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

-0.56

-0.76

-1.37

-2.22

-4.80

Intersect ENT Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EPS (Basic)	Get a 7-Day Free Trial															-0.61	-0.50	-0.95	-2.74	-0.85

Intersect ENT EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Intersect ENT's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-159.635	-	0)	/	33.272
	=	-4.80

Intersect ENT's Basic EPS for the quarter that ended in Mar. 2022 is calculated as

Basic EPS (Q: Mar. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-28.804	-	0)	/	33.735
	=	-0.85

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.04

Intersect ENT (NAS:XENT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Intersect ENT EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Intersect ENT's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Intersect ENT (Intersect ENT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Adams Drive, Menlo Park, CA, USA, 94025

Website

https://www.intersectent.com

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.

Executives

Elisabeth Sandoval	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi	director	1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez	officer: Chief Human Resource Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick	officer: EVP, GC & Corporate Secretary	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West	director, officer: President and CEO	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier	officer: EVP & Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr	officer: Vice President, Sales	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson	officer: Vice President, Marketing	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt	director, officer: See Remarks	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman	officer: Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski	officer: Chief Operations Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman	officer: See Remarks	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden	officer: Chief People Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025